From HAS website:
https://www.has-sante.fr/jcms/p_3213581/fr/distinguer-la-grippe-de-la-covid-19-dans-quelles-situations-et-avec-quels-tests
"The HAS considers that there is an interest in looking for one or more viruses of winter respiratory infections (including influenza) in association with a search for SARS-CoV-2 in only patients who present symptoms and for whom the result will be useful for determining the nature of the care and / or a particular isolation: adults hospitalized or arriving in emergencies, residents in EHPAD and young children. In other people, the identification of the winter virus virus does not have any consequences on the management which is based on the treatment of the symptoms and the monitoring of the evolution of the disease, the use of these tests is unnecessary. Only a detection test for SARS-CoV-2 is then indicated."
"In hospitalized adults, in emergencies or living in collective establishments, adapt isolation and care
In the hospital, whether it is during the hospitalization of an adult patient or upon arrival at the emergency room, faced with symptoms suggestive of a respiratory infection, it is important to identify the virus in question specifically to isolate the patient correctly and undertake the most appropriate management. In this situation, performing RT-PCR tests for SARS-CoV-2 and any other virus responsible for winter viral infections is indicated upon arrival at the hospital. It is recalled that a SARS-CoV-2 antigen test can also be used in emergencies.
Faced with an adult residing in a social or medico-social establishment, a double COVID-19 and influenza test should be carried out in the presence of symptoms suggestive of these two pathologies. The test will then be antigenic or RT-PCR for the detection of SARS-CoV-2, and RT-PCR for the detection of influenza."
19/10/2020 10:02
Due to a technical issue, trading has been halted on all Euronext products until further notice.
We are working to resolve this issue and we will provide an update as soon as possible regarding the expected pre-opening time and resumption of trading.
Before any trading resumption, there will be a pre-opening phase of at least 15 minutes.
Major holding declaration on Euronext:
https://www.amf-france.org/en/professionals/professional-investor/my-relations-amf/major-holding
"The regulations, in short
Whenever a shareholder, acting alone or in concert, reaches, exceeds or falls below the legal thresholds of (i) 5%, 10%, 15%, 20%, 25%, 30%, 1/3, 50%, 2/3, 90% or 95% of the equity or voting rights of an issuer whose shares are admitted to trading on Euronext Paris, or (ii) 50% or 95% of the equity or voting rights of an issuer whose shares are admitted to trading on Euronext Growth, it must report this to the company and to the AMF; this report must reach the AMF no later than before the close of trade on the fourth trading day following the day of the threshold crossing, and must be sent to the company within this deadline."
To bounce back on what B2HS2L said, now we can also cross-sell our tests to non-Novacyt customers who bought MyGoPro machines via IT-IS distribution network. So we increased our reach in the market as well
These I believe are distributors for Q16 and Q32 (Don't want to call them MyGoPro anymore :-) ) :
USA: https://midsci.com/products/364/qPCR-Thermal-Cyclers/
Spain: http://www.ecogen.com/productos2.asp?id_categoria=310
I agree with you B2HS2L
I think there are many good reasons behind the acquisition of IT-IS:
- How the whole solution of a Mid-Cap for the government rely on such a small manufacturer? this was too risky for GM.
- That risk apparently didn't need to be mitigated earlier as we got the NHS contract (300 machines first) without it.
But if you include care homes (2000 right ? so 2000 machines) and the additional 700 machines for NHS then it starts to be risky. It is a clear indication to me that the care homes contract is coming soon!
- Plus GM can now improve the machine, make it faster, add functionality, develop synergies with the tests to make things simpler and control the end to end process ... Also start economies of scale, apply PrimerDesign recipee for growth margins...
Well that's all positive to me and foresees a bright future !
What a great acquisition in the spirit of Primerdesign's...
As they know each other for 5 years already, it might be easy to integrate.
Besides securing the IP, now we will have full freedom to improve the products
I think it was a pre-requisite announcement prior to the care homes contract ! :-)
France is also adding Antigen testing to its arsenal.
https://www.thelocal.fr/20201001/will-the-new-covid-19-antigen-tests-solve-frances-testing-headache
I believe GM will trigger the RNS on Thursday so he can get the fireworks by Friday night
I listened again to the AGM just to hear again GM's conclusion:
"I want to thank all of our shareholders and employees for supporting the company through this transformative change.
I must add that we are at the beginning and not at the end of this change "
If we assume that a vaccine will arrive quickly, let's say January (which I doubt), only a few people will have access to the vaccine in 2021... so long life to diagnostics tests...
"In mid-September, the big boss of the Serum Institute, an Indian pharmaceutical company that is the world's sixth-largest vaccine producer, told the Financial Times that it would take until 2024 to have enough vaccines for the entire population of the planet, due to current production limits. The Pfizer-BioNtech consortium, for its part, has mentioned 1.3 billion doses in 2021, which would cover only 650 million people if two doses are required..."
As a reminder, the world population is 7.8 Bn people.
Interesting article from Canada (in French)
https://www.lapresse.ca/covid-19/2020-10-11/le-point-sur-le-vaccin-contre-la-covid-19.php
My expectation is at least £15 by December thanks to a few nice contracts (care homes, France, Commonwealth countries, ...) or acquisitions along the way . Around £20 end of Jan once H2 2020 sales results are announced because we should have a nice surprise.
IMO we will reach £15 by end December thanks to a few nice contracts (care homes, France, Commonwealth countries, ...) or acquisitions along the way . But the fireworks will be in January when GM announces S2 2020 results. He usually plays down the numbers and i believe we'll get a nice surprise... and boom £20.
" These tests are needed immediately in response to this crisis and need to be implemented to support the NHS’s ability to manage the increase of positive cases in hospitals, to be able to identify and treat Covid-19 positive patients and isolate them from other patients in hospitals. These allow NHS to save lives."
These are the tenders which were announced during the AGM, right !?
Because such bigs contracts should be related to a tender anyway and these are the only tenders allocated to PrimerDesign.
I think it is just the formalization of what was previously announced at the AGM.